BIRC5 and chronic myelogenous leukemia, BCR-ABL1 positive: PRI-724 treatment has been shown to downregulate survivin expression in several of these cancers, such as hepatocellular carcinoma [36,37], osteosarcoma [35], SARS-CoV-2-infected lung adenocarcinoma cells [39], and acute and chronic myeloid leukemia [40,41].